SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Financials Shin Nippon Biomedical Laboratories, Ltd.
Equities
2395
JP3379950003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,502 JPY | +1.49% |
|
+5.55% | -11.54% |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 37,511 | 21,982 | 29,101 | 70,608 | 114,488 | 62,531 | - | - |
| Enterprise Value (EV) 1 | 48,320 | 31,655 | 34,500 | 72,748 | 122,715 | 82,040 | 81,458 | 78,544 |
| P/E ratio | 19.2 x | 8.62 x | 7.95 x | 9.91 x | 18.9 x | 15.7 x | 11.8 x | 8.69 x |
| Yield | 0.33% | 0.95% | 2.86% | 2.36% | 1.82% | 3.33% | 3.33% | 4.33% |
| Capitalization / Revenue | 2.4 x | 1.51 x | 1.93 x | 3.98 x | 4.56 x | 2.39 x | 1.99 x | 1.79 x |
| EV / Revenue | 3.09 x | 2.17 x | 2.28 x | 4.1 x | 4.89 x | 3.13 x | 2.59 x | 2.24 x |
| EV / EBITDA | - | - | - | - | 18.1 x | 14.8 x | 11.1 x | 7.43 x |
| EV / FCF | 37,749,621 x | 21,047,038 x | 9,271,647 x | 17,121,190 x | -76,220,422 x | - | 30,577,388 x | 13,975,829 x |
| FCF Yield | 0% | 0% | 0% | 0% | -0% | - | 0% | 0% |
| Price to Book | 1.32 x | 1.35 x | 1.85 x | 3.61 x | 4.37 x | 2.22 x | 2 x | 1.75 x |
| Nbr of stocks (in thousands) | 41,632 | 41,632 | 41,632 | 41,632 | 41,632 | 41,632 | - | - |
| Reference price 2 | 901.0 | 528.0 | 699.0 | 1,696 | 2,750 | 1,502 | 1,502 | 1,502 |
| Announcement Date | 5/10/19 | 5/11/20 | 5/10/21 | 5/6/22 | 5/8/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15,658 | 14,561 | 15,110 | 17,748 | 25,090 | 26,190 | 31,500 | 35,000 |
| EBITDA 1 | - | - | - | - | 6,789 | 5,540 | 7,370 | 10,570 |
| EBIT 1 | 829 | 2,228 | 2,529 | 4,195 | 5,245 | 3,470 | 4,500 | 7,500 |
| Operating Margin | 5.29% | 15.3% | 16.74% | 23.64% | 20.9% | 13.25% | 14.29% | 21.43% |
| Earnings before Tax (EBT) 1 | 1,650 | 3,062 | 4,175 | 8,183 | 7,759 | 5,490 | 7,100 | 10,200 |
| Net income 1 | 1,950 | 2,550 | 3,661 | 7,127 | 6,060 | 3,975 | 5,300 | 7,200 |
| Net margin | 12.45% | 17.51% | 24.23% | 40.16% | 24.15% | 15.18% | 16.83% | 20.57% |
| EPS 2 | 46.84 | 61.25 | 87.95 | 171.2 | 145.6 | 95.50 | 127.3 | 172.9 |
| Free Cash Flow | 1,280 | 1,504 | 3,721 | 4,249 | -1,610 | - | 2,664 | 5,620 |
| FCF margin | 8.17% | 10.33% | 24.63% | 23.94% | -6.42% | - | 8.46% | 16.06% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 36.15% | 53.17% |
| FCF Conversion (Net income) | 65.64% | 58.98% | 101.64% | 59.62% | - | - | 50.26% | 78.06% |
| Dividend per Share 2 | 3.000 | 5.000 | 20.00 | 40.00 | 50.00 | 50.00 | 50.00 | 65.00 |
| Announcement Date | 5/10/19 | 5/11/20 | 5/10/21 | 5/6/22 | 5/8/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,389 | 7,003 | 7,961 | 4,985 | 4,046 | 6,302 | 10,348 | 6,023 | 8,718 | 5,805 | 6,079 | 11,884 | 6,100 | 8,205 | 7,300 | 7,400 | 14,700 | 7,550 | 9,250 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,078 | 1,161 | 1,969 | 1,331 | 714 | 1,599 | 2,313 | 1,470 | 1,461 | 1,227 | 1,122 | 2,349 | 186 | 934 | 1,000 | 950 | 1,950 | 850 | 1,700 |
| Operating Margin | 16.87% | 16.58% | 24.73% | 26.7% | 17.65% | 25.37% | 22.35% | 24.41% | 16.76% | 21.14% | 18.46% | 19.77% | 3.05% | 11.38% | 13.7% | 12.84% | 13.27% | 11.26% | 18.38% |
| Earnings before Tax (EBT) | 1,252 | 1,300 | 3,905 | 2,139 | 2,771 | 3,119 | 5,890 | -259 | 2,128 | 1,941 | 1,872 | 3,814 | 1,124 | - | 1,600 | 1,550 | 3,150 | 1,850 | 2,100 |
| Net income 1 | 877 | 1,139 | 3,503 | 1,744 | 1,944 | 2,475 | 4,419 | -68 | 1,708 | 1,373 | 1,593 | 2,966 | 828 | 180 | 1,200 | 1,170 | 2,370 | 1,510 | 1,420 |
| Net margin | 13.73% | 16.26% | 44% | 34.98% | 48.05% | 39.27% | 42.7% | -1.13% | 19.59% | 23.66% | 26.2% | 24.96% | 13.57% | 2.19% | 16.44% | 15.81% | 16.12% | 20% | 15.35% |
| EPS | 21.07 | 27.36 | 84.15 | 41.90 | 46.70 | - | 106.2 | -1.640 | 41.04 | 32.98 | 38.26 | 71.24 | 19.90 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | 20.00 | - | - | - | - | 20.00 | - | - | - | - | - | - | - |
| Announcement Date | 11/8/19 | 11/6/20 | 11/2/21 | 2/2/22 | 7/29/22 | 10/31/22 | 10/31/22 | 1/31/23 | 5/8/23 | 8/2/23 | 11/7/23 | 11/7/23 | 2/2/24 | - | - | - | - | - | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 10,809 | 9,673 | 5,399 | 2,140 | 8,227 | 19,509 | 18,927 | 16,013 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 1.212 x | 3.521 x | 2.568 x | 1.515 x |
| Free Cash Flow | 1,280 | 1,504 | 3,721 | 4,249 | -1,610 | - | 2,664 | 5,620 |
| ROE (net income / shareholders' equity) | 7.1% | 11.4% | 22.9% | 40.4% | 26.5% | 14.6% | 17.8% | 21.4% |
| ROA (Net income/ Total Assets) | 2.88% | 6.69% | 9.6% | 18.6% | 19% | 10.2% | 10.1% | 14.1% |
| Assets 1 | 67,662 | 38,128 | 38,154 | 38,406 | 31,821 | 38,971 | 52,475 | 51,064 |
| Book Value Per Share 2 | 682.0 | 391.0 | 378.0 | 470.0 | 630.0 | 675.0 | 752.0 | 860.0 |
| Cash Flow per Share | 79.50 | 90.80 | 116.0 | 199.0 | 183.0 | - | - | - |
| Capex 1 | 1,612 | 1,514 | 1,025 | 1,703 | 5,614 | 10,000 | 3,500 | 3,000 |
| Capex / Sales | 10.3% | 10.4% | 6.78% | 9.6% | 22.38% | 38.18% | 11.11% | 8.57% |
| Announcement Date | 5/10/19 | 5/11/20 | 5/10/21 | 5/6/22 | 5/8/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,502
JPY
Average target price
3,150
JPY
Spread / Average Target
+109.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.54% | 397M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 2395 Stock
- Financials Shin Nippon Biomedical Laboratories, Ltd.
